ArticleAnnals of surgical oncology2026
Exploring the Link Between Stress-Induced Naive T-Cells and Esophageal Squamous Cell Carcinoma Risk: A Multi-Omics Investigation.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Recurrent laryngeal nerve lymph nodes status prediction after neoadjuvant therapy for thoracic esophageal squamous cell carcinoma.Insights into imaging · 2026Article
- Immune exhaustion in esophageal cancer: interferon pathway dysregulation and neoadjuvant therapy response.Frontiers in cell and developmental biology · 2026Review
- ASO Author Reflections: Reconsidering Late Recurrence After Hepatectomy for Hepatocellular Carcinoma: Insights from Predictive Modeling.Annals of surgical oncology · 2025Article
- ASO Author Reflections: Aligning Cancer Therapy with Biologic Time: Reflections on Circadian Oncology.Annals of surgical oncology · 2025Article
- ASO Author Reflections: Research on the Inhibitory Effect of Eupatilin on Osteosarcoma Cells from the Perspective of Non-coding Genes and the Potential of Nanodrug Delivery Systems for Osteosarcoma Treatment.Annals of surgical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe dynamic crosstalk between immunoregulatory constituents and neoplastic evolution underscores the centrality of immune homeostasis in oncogenesis. naïve T-lymphocytes, as primary architects of adaptive immunity, are critically implicated in antitumor responses. Deciphering their mechanistic linkage to esophageal carcinogenesis is vital for elucidating immune-mediated susceptibility and malignant progression. This investigation synergizes Mendelian randomization with single-cell multi-omics to dissect this pathobiological nexus.
methodsA bidirectional two-sample Mendelian randomization framework was deployed to infer causal associations between leukocyte subsets and esophageal squamous cell carcinoma. Genome-wide summary statistics were analyzed from 476,306 malignancy cases and immunophenotypic data spanning 731 European-ancestry participants. Complementary single-cell transcriptional profiling of tumor-adjacent dyads provided mechanistic validation.
resultsInverse variance-weighted regression demonstrated a positive causal effect of naive T-cell abundance on esophageal cancer risk (odds ratio 1.14; 95% confidence interval 1.03-1.27; P = 0.021). Single-cell analyses unveiled tumor-infiltrating naïve T-lymphocytes in a metabolically quiescent state with suppressed effector differentiation trajectories, indicative of microenvironment-driven anergy. This functional impairment correlated with compromised immunoediting capacity, potentiating neoplastic immune evasion mechanisms.
conclusionsOur integrative analysis establishes naïve T-cell abundance as a novel causal risk factor for esophageal squamous cell carcinoma, mediated through metabolic silencing and differentiation blockade within the tumor niche. These findings redefine the immunopathogenic paradigm of esophageal carcinogenesis, suggesting that therapeutic strategies targeting T-cell metabolic reprogramming may disrupt immune-evasion pathways. The demonstrated synergy between population-level genetic inference and single-cell mechanistic validation provides a transformative framework for cancer immunology research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.